Chicago Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.3M Buy
90,790
+12,102
+15% +$1.91M 5.1% 3
2026
Q2
$12.5M Buy
+78,688
New +$10.6M 4.42% 10
2023
Q1
– Sell
-50,738
Closed -$4.21M – 50
2022
Q4
$4.21M Buy
50,738
+3,981
+9% +$322K 3.63% 10
2022
Q3
$3.71M Buy
+46,757
New +$3.94M 3.55% 11

Other funds holding XBI

Chicago Wealth Management's XBI Position: Q3 2026 in Review

Chicago Wealth Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 15% in Q3 2026, buying an estimated $1.91M and bringing the position to 90,790 shares worth $14.3M. The position accounts for 5.1% of the portfolio, ranked #3.

Chicago Wealth Management first reported a position in XBI in Q3 2022 and has held it in 4 quarters since. 960 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Chicago Wealth Management held 90,790 shares of State Street SPDR S&P Biotech ETF worth $14.3M as of Q3 2026.
  • Chicago Wealth Management bought 12,102 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $1.91M.
  • State Street SPDR S&P Biotech ETF made up 5.1% of Chicago Wealth Management's portfolio in Q3 2026, its #3 holding.
  • Chicago Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2022 and has held it in 4 quarters since.
  • 960 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Chicago Wealth Management's 13F filing for Q3 2026, filed 17 Nov 2026.